Table 2 TKI therapies and tumor mutational status of the cohort
Mutational status of primary tumors | Mutational status of resistant metastatic tumors | Death or not at the last follow-up | TKI therapy after CRS | |
|---|---|---|---|---|
Case 1 | KIT exon 9 | KIT exon 9 | No | Imatinib |
Case 2 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib + Regorafenib |
Case 3 | KIT exon 9 | KIT exon 9 | Yes | Sunitinib |
Case 4 | KIT exon 11 | KIT exon 11 + 17 | Yes | Sunitinib + Regorafenib + Dasatinib |
Case 5 | KIT exon 9 | KIT exon 9 | No | Imatinib + Sunitinib |
Case 6 | KIT exon 11 | KIT exon 11 + 13 | No | Sunitinib |
Case 7 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib |
Case 8 | KIT exon 11 | KIT exon 11 | No | Imatinib |
Case 9 | KIT exon 11 | KIT exon 11 + 17 | No | Sunitinib |
Case 10 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib |
Case 11 | KIT exon 11 | KIT exon 11 | No | Imatinib + Sunitinib + Ripretinib |
Case 12 | KIT exon 11 + PDGFRA | KIT exon 11 + PDGFRA | No | Sunitinib |
Case 13 | KIT exon 17 | KIT exon 17 | No | Imatinib + Dasatinib + Regorafenib |
Case 14 | Wild type | Wild type | Yes | Imatinib + Sunitinib + Dasatinib |
Case 15 | Wild type | Wild type | Yes | Imatinib + Sunitinib + Dasatinib |